News|Articles|November 16, 2026

Optune Pax Delayed Pain in Locally Advanced Pancreatic Cancer

Fact checked by: CURE staff
Listen
0:00 / 0:00

Key Takeaways

  • PANOVA-3 randomized 571 patients with locally advanced pancreatic adenocarcinoma to gemcitabine/nab-paclitaxel with or without Optune Pax worn ≥18 hours/day using abdominal arrays delivering tumor treating fields.
  • Patient-reported time to deterioration improved with Optune Pax for general pain (10.1 vs 7.4 months), pancreas-specific pain (14.7 vs 10.2 months), and global quality of life (7.1 vs 5.7 months).
SHOW MORE

In a secondary analysis of a phase 3 trial published Nov. 13, 2026, people with locally advanced pancreatic cancer who wore the Optune Pax device with chemotherapy went about three months longer before their pain worsened than those who had chemotherapy alone.

If you are living with pancreatic cancer that cannot be removed with surgery, keeping pain under control is often as important as slowing the cancer itself. A new analysis published Nov. 13, 2026, in JAMA Network Open found that adding a wearable device called Optune Pax to standard chemotherapy helped people go noticeably longer before their pain got worse.

The findings come from PANOVA-3, a phase 3 trial (a large study that randomly assigns patients to different treatments) of 571 people with locally advanced pancreatic adenocarcinoma, the most common type of pancreatic cancer. "Locally advanced" means the tumor has grown into nearby blood vessels or tissue, so surgery is not an option, but it has not spread to distant organs. Everyone in the trial received the chemotherapy drugs gemcitabine and nab-paclitaxel (Abraxane). Half also wore Optune Pax.

How the Device Works

Optune Pax delivers tumor treating fields, which are gentle, low-intensity electric fields aimed at the belly area. The fields are designed to interfere with cancer cells as they try to divide. The device is portable and is carried in a shoulder bag or backpack, and it connects to adhesive pads, called arrays, that are placed on the skin.

In the trial, patients were asked to wear the arrays at least 18 hours a day. The arrays were changed two to three times a week and shifted slightly each time to protect the skin. The main side effect was skin irritation under the arrays, which was mostly mild to moderate. The device did not add the kind of whole-body side effects that come with chemotherapy.

How Much Longer Pain Stayed in Check

Researchers looked at "time to deterioration," meaning how long it took before a patient's own ratings of pain or well-being got meaningfully worse on standard questionnaires.

For general pain, the typical patient wearing the device went 10.1 months before pain worsened, compared with 7.4 months for those on chemotherapy alone. For pain specific to pancreatic cancer, such as belly and back pain, it was 14.7 months vs. 10.2 months. Overall quality of life also held steady longer: 7.1 months vs. 5.7 months.

The team also looked at pain medicine. People who used the device started opioids (strong prescription pain relievers) a median of 9.3 months into treatment, compared with 6.7 months for those on chemotherapy alone. At one year, 37.2% of patients in the device group had not needed opioids, compared with 29.5% in the chemotherapy-only group.

Not everything improved. The researchers saw no difference in fatigue, sleep or body image, and patients in both groups reported more trouble keeping up with daily roles over time. The authors suggested that fitting a wearable device into everyday life may play a part.

Where This Fits With Earlier Results

This analysis adds to the main PANOVA-3 results, which showed that people using the device lived a median of 16.2 months, compared with 14.2 months with chemotherapy alone. Those survival results led the FDA to approve Optune Pax for locally advanced pancreatic cancer in February 2026. CURE covered that decision in FDA Approves Optune Pax for Locally Advanced Pancreatic Cancer.

There are limits to keep in mind. Patients and doctors knew who was wearing the device, and there was no fake (sham) device for comparison, which can shape how people rate their symptoms. The opioid findings came from an extra analysis that was not planned when the trial began. And fewer patients were still filling out surveys as time went on.

Is It Right for You?

Optune Pax is available now by prescription for adults with locally advanced pancreatic cancer, used together with gemcitabine and nab-paclitaxel. It is not approved for pancreatic cancer that has spread to other organs or for cancer that can be removed with surgery.

Wearing the device most of the day is a real commitment, so it helps to think through practical questions with your care team: how the arrays will fit with your clothing, sleep and work, who will help change them, and what to do if your skin gets sore. If pain is already a problem, ask about a referral to palliative care, a specialty focused on symptom relief that can be added at any stage of treatment.

For a look at life with this disease from a patient's side, CURE has shared one survivor's pancreatic cancer journey.

References

  1. Macarulla T, et al. "Tumor Treating Fields and Quality of Life Among Patients With Locally Advanced Pancreatic Adenocarcinoma: A Secondary Analysis of a Randomized Clinical Trial." JAMA Network Open. Nov. 13, 2026.

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.


Related to this article